Consistent with these findings, our analysis revealed uniformly negative associations between PEBP1/STK11 co-expression and the expression of genes encoding immune checkpoint molecules across all cancer types examined, suggesting that their co-expression may contribute to the development of a more immunocompetent and less suppressive TME. The gene discussed is STK11; the disease is cancer.